Radiopharmaceuticals for Nuclear Medicine

This tender concerns the supply of radiopharmaceuticals essential for nuclear medicine procedures. Radiopharmaceuticals are specialized radioactive drugs used in diagnostic imaging and therapeutic applications within nuclear medicine. They are administered to patients to visualize organs, assess physiological functions, or treat specific diseases, particularly cancers. The procurement aims to ensure a consistent and reliable supply of these critical materials, which are vital for the accurate diagnosis and effective treatment of a wide range of medical conditions. The scope of the tender likely includes various types of radiopharmaceuticals, potentially covering both diagnostic agents (e.g., for PET and SPECT imaging) and therapeutic agents (radiotherapeutics). Key requirements may involve adherence to stringent quality control standards, specific packaging and delivery protocols to maintain radioactive integrity, and compliance with all relevant national and international regulations governing the handling and use of radioactive materials. The successful bidder will be expected to demonstrate robust supply chain management capabilities and a commitment to patient safety. This procurement is crucial for healthcare providers relying on advanced nuclear medicine techniques to deliver high-quality patient care.

This is a supplies contract in the health and medical services sector, with a focus on Pharmaceuticals. Located in Spain, Europe, this opportunity is open to firms and consortiums.

Published through TED - Tenders Electronic Daily (EU), a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.